tms-japan.co.jp
Contact us
About company
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.
NL
Unknown
Not verified company
